PATENT CLAIM ANALYSIS

Application Number: 16194625
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "248000"]

Abstract:
Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.

Claim (Index 11):
The composition of  claim 1 , wherein said GABA(A) alpha composition is in the form of an intranasal formulation.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 98.0
- Lexical Diversity: 1.45918
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15818850', '14994705', '13362656', '13912874', '12454202']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.747883477826082
- 35 USC 102 Novelty (BERT): 0.5220929637312799
- Combined Prediction Score: 0.7253044264166018
- Mean Citation Score: 265.54608799999994
- Max Citation Score: 295.75177
- Similarity Product: 213.7593361451352

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test